Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat

FOSTER CITY, Calif.--(BUSINESS WIRE) June 20, 2023 -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the submission to the United States Food and Drug Administration (FDA) of a New Drug Application...

https://www.drugs.com/nda/imetelstat_230620.html

Source: Drugs.com - New Drug Applications - June 20, 2023 Category: Drugs & Pharmacology Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | New Drug Applications | USA Health